CLINICAL_TRIALS
trial_result
· 2022-08-08
Clinical Trial Update: A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
Summary
A phase 1/2 trial of brequinar in relapsed/refractory acute myeloid leukemia (AML) was terminated with posted results in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Clear Creek Bio, Inc. | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-08-08